Bill > A00686

This bill ensures that ovarian cancer survivors have the right to comprehensive genetic and genomic testing without restrictions. Specifically, the bill prohibits denying ovarian cancer survivors genetic testing or genomic tumor profiling to identify inherited (germline) and acquired (somatic) mutations. The required testing must include screenings for specific genetic mutations such as BRCA1 and BRCA2 genes (which are known to significantly increase cancer risk), mutations associated with Lynch syndrome, and a comprehensive rearrangement analysis of genetic coding associated with ovarian cancer. Additionally, healthcare professionals would have the discretion to order additional mutation tests if they determine such testing is medically necessary and appropriate for the individual patient. By removing frequency caps and other potential limitations, the bill aims to provide ovarian cancer survivors with more thorough and personalized medical screening options that could help detect potential future cancer risks or recurrences.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A686